BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 318.2 SEK -1.85%
Market Cap: 28.1B SEK

Operating Margin
BioArctic AB

61.2%
Current
4%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
61.2%
=
Operating Profit
1.2B
/
Revenue
1.9B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
BioArctic AB
STO:BIOA B
27.9B SEK
61%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
396.2B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
147.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
28%
AU
CSL Ltd
ASX:CSL
84B AUD
26%
NL
argenx SE
XBRU:ARGX
45.1B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD
8%
No Stocks Found

BioArctic AB
Glance View

Market Cap
28.2B SEK
Industry
Biotechnology

In the heart of Sweden, BioArctic AB carves its niche as a pioneering biopharmaceutical company with a resolute focus on neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Founded in 2003 by the innovative minds of Professor Lars Lannfelt and Dr. Pär Gellerfors, the company draws on cutting-edge science to develop novel treatments that target the underlying causes of these debilitating conditions. BioArctic’s scientific journey is rooted in its strategic use of monoclonal antibodies to halt or reverse the progression of neurological diseases. By zeroing in on the amyloid beta proteins and alpha-synuclein aggregates that play significant roles in Alzheimer’s and Parkinson’s diseases, respectively, BioArctic aims to provide therapies that go beyond mere symptom management to address the fundamental disease processes. At the core of BioArctic’s financial engine lies its collaborative business model, where strategic partnerships with pharmaceutical giants like Eisai and AbbVie are pivotal. These alliances not only bolster BioArctic’s research capabilities but also generate substantial revenue through milestone payments and royalties. Such collaborations allow BioArctic to leverage the vast distribution networks and financial muscle of its partners, facilitating the global commercialization of its therapies once they achieve regulatory approval. As the company continues to advance its pipeline through rigorous clinical trials, its combination of scientific rigor and strategic partnerships positions it as a formidable player in the quest to unravel and treat complex neurodegenerative diseases. Through its relentless innovation and well-crafted alliances, BioArctic stands at the forefront of transforming medical treatment for millions worldwide.

BIOA B Intrinsic Value
157.16 SEK
Overvaluation 51%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
61.2%
=
Operating Profit
1.2B
/
Revenue
1.9B
What is the Operating Margin of BioArctic AB?

Based on BioArctic AB's most recent financial statements, the company has Operating Margin of 61.2%.

Back to Top